Advertisement

Analytical and Bioanalytical Chemistry

, Volume 410, Issue 14, pp 3375–3384 | Cite as

Degradation product characterization of therapeutic oligonucleotides using liquid chromatography mass spectrometry

  • N. M. Elzahar
  • N. Magdy
  • Amira M. El-Kosasy
  • Michael G. Bartlett
Research Paper

Abstract

Synthetic antisense phosphorothioate oligonucleotides (PS) have undergone rapid development as novel therapeutic agents. The increasing significance of this class of drugs requires significant investment in the development of quality control methods. The determination of the many degradation pathways of such complex molecules presents a significant challenge. However, an understanding of the potential impurities that may arise is necessary to continue to advance these powerful new therapeutics. In this study, four different antisense oligonucleotides representing several generations of oligonucleotide therapeutic agents were evaluated under various stress conditions (pH, thermal, and oxidative stress) using ion-pairing reversed-phase liquid chromatography tandem mass spectrometry (IP-RPLC-MS/MS) to provide in-depth characterization and identification of the degradation products. The oligonucleotide samples were stressed under different pH values at 45 and 90 °C. The main degradation products were observed to be losses of nucleotide moieties from the 3′- and 5′-terminus, depurination, formation of terminal phosphorothioates, and production of ribose, ribophosphorothioates (Rp), and phosphoribophosphorothioates (pRp). Moreover, the effects of different concentrations of hydrogen peroxide were studied resulting in primarily extensive desulfurization and subsequent oxidation of the phosphorothioate linkage to produce the corresponding phosphodiester. The reaction kinetics for the degradation of the oligonucleotides under the different stress conditions were studied and were found to follow pseudo-first-order kinetics. Differences in rates exist even for oligonucleotides of similar length but consisting of different sequences.

Graphical abstract

Identification of degradation products across several generations of oligonucleotide therapeutics using LC-MS

Keywords

Antisense Chemical stability Ion-pair chromatography LC/MS/MS Phosphorothioate oligonucleotides 

Notes

Acknowledgements

The authors would like to thank ProQR Therapeutics and Ionis Pharmaceuticals for their support of this work. Also, the authors would like to thank the Egyptian Joint Supervision Missions Department of the Ministry of Higher Education, Cairo, Egypt.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

216_2018_1032_MOESM1_ESM.pdf (1.4 mb)
ESM 1 (PDF 1.34 mb)

References

  1. 1.
    Crooke ST. Progress in antisense therapeutics. Med Res Rev. 1996;16:319–44.CrossRefPubMedGoogle Scholar
  2. 2.
    Opalinska JB, Gewirtz AM. Nucleic-acid therapeutics: basic principles and recent applications. Nat Rev Drug Discov. 2002;1:503–14.CrossRefPubMedGoogle Scholar
  3. 3.
    Mansoor M, Melendez AJ. Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics. Gene Regul Syst Biol. 2008;2:275–95.Google Scholar
  4. 4.
    Wilson C, Keefe AD. Building oligonucleotide therapeutics using non-natural chemistries. Curr Opin Chem Biol. 2006;10:607–14.CrossRefPubMedGoogle Scholar
  5. 5.
    Levin D. Oligonucleotide stability and degradation. In: Okafo G, Elder D, Webb M, editors. Analysis of oligonucleotides and their related substances. Hertfortshire, UK: ILM Publications; 2013. p. 271–96.Google Scholar
  6. 6.
    Capaldi D. Stress testing of oligonucleotides. In: Baertschi SW, Alsante KM, Reed RA, editors. Pharmaceutical stress testing: predicting drug degradation. second ed. UK: Informa healthcare; 2011. p. 391–425.Google Scholar
  7. 7.
    Davis DL, O'Brien EP, Bentzley CM. Analysis of the degradation of oligonucleotide strands during the freezing/thawing processes using MALDI-MS. Anal Chem. 2000;72:5092–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Friese OV, Sperry JB, He Y, Joseph L, Carroll JA, Rouse JC. Characterization of apolipoprotein C3 (Apo C3) LNA/DNA impurities and degradation products by LC-MS/MS. AAPS J. 2017;9:1735–44.CrossRefGoogle Scholar
  9. 9.
    An R, Jia Y, Wan B, Zhang Y, Dong P, Li J, et al. Non-enzymatic depurination of nucleic acids: factors and mechanisms. PLoS One. 2014;9:e115950.Google Scholar
  10. 10.
    Suzuki T, Ohsumi S, Makino K. Mechanistic studies on depurination and apurinic site chain breakage in oligodeoxyribonucleotides. Nucleic Acids Res. 1994;22:4997–5003.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Loeb LA, Preston BD. Mutagenesis by apurinic/apyrimidinic sites. Annu Rev Genet. 1986;20:201–30.CrossRefPubMedGoogle Scholar
  12. 12.
    Krotz AH, Mehta RC, Hardee GE. Peroxide-mediated desulfurization of phosphorothioate oligonucleotides and its prevention. J Pharm Sci. 2005;94:341–52.CrossRefPubMedGoogle Scholar
  13. 13.
    Rentel C, Wang X, Batt M, Kurata C, Oliver J, Gaus H, et al. Formation of modified cytosine residues in the presence of depurinated DNA. J Org Chem. 2005;70:7841–5.Google Scholar
  14. 14.
    Cadet J, Ravanat JL, Martinez GR, Medeiros MH, Di Mascio P. Singlet oxygen oxidation of isolated and cellular DNA: product formation and mechanistic insights. Photochem Photobiol. 2006;82:1219–25.CrossRefPubMedGoogle Scholar
  15. 15.
    Cadet J, Douki T, Ravanat JL. Oxidatively generated damage to the guanine moiety of DNA: mechanistic aspects and formation in cells. Acc Chem Res. 2008;41:1075–83.CrossRefPubMedGoogle Scholar
  16. 16.
    Mangano MF, Battaglia C, Salani G, Bernardi LR, De Bellis G. Composition dependent separation of oligonucleotides by capillary electrophoresis in acidic buffers with application to the quality control of synthetic oligonucleotides. J Chromatogr A. 1999;848:435–42.CrossRefGoogle Scholar
  17. 17.
    Gelfi C, Perego M, Morelli S, Nicolin A, Righetti PG. Analysis of antisense oligonucleotides by capillary electrophoresis, gel-slab electrophoresis, and HPLC: a comparison. Antisense Nucleic Acid Drug Dev. 1996;6:47–53.CrossRefPubMedGoogle Scholar
  18. 18.
    Gilar M, Fountain KJ, Budman Y, Holyoke JL, Davoudi H, Gebler JC. Characterization of therapeutic oligonucleotides using liquid chromatography with on-line mass spectrometry detection. Oligonucleotides. 2003;13:229–43.CrossRefPubMedGoogle Scholar
  19. 19.
    Studzińska S, Buszewski B. Evaluation of ultra high-performance liquid chromatography columns for the analysis of unmodified and antisense oligonucleotides. Anal Bioanal Chem. 2014;406:7127–36.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Deng P, Chen X, Zhang G, Zhong D. Bioanalysis of an oligonucleotide and its metabolites by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2010;52:571–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Metelev V, Agrawal S. Ion-exchange high-performance liquid chromatography analysis of oligodeoxyribonucleotide phosphorothioates. Anal Biochem. 1992;200:342–6.CrossRefPubMedGoogle Scholar
  22. 22.
    McGinnis AC, Cummings BS, Bartlett MG. Ion-exchange liquid chromatography method for the direct determination of small ribonucleic acids. Anal Chim Acta. 2013;799:57–67.CrossRefPubMedGoogle Scholar
  23. 23.
    Thayer JR, Barreto V, Rao S, Pohl C. Control of oligonucleotide retention on a pH-stabilized strong anion exchange column. Anal Biochem. 2005;33:39–47.CrossRefGoogle Scholar
  24. 24.
    Gong L, McCullagh JSO. Analysis of oligonucleotides by hydrophilic inetraction coupled to negative ion electrospray ionization mass spectrometry. J Chromatogr A. 2011;1218:5480–6.CrossRefPubMedGoogle Scholar
  25. 25.
    Easter RN, kreoning KK, Caruso JA, limbach PA. Separation and identification of oligonucleotides by hydrophilic interaction liquid chromatography (HILIC)-inductively coupled plasma mass spectrometry (ICPMS). Analyst. 2010;135:2560–5.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    McGinnis AC, Chen B, Bartlett MG. Chromatographic methods for the determination of therapeutic oligonucleotides. J Chromatogr B. 2012;883-884:76–94.CrossRefGoogle Scholar
  27. 27.
    Basiri B, Bartlett MG. LC-MS of oligonucleotides: applications in biomedical research. Bioanalysis. 2014;6:1525–42.CrossRefPubMedGoogle Scholar
  28. 28.
    Erb R, Oberacher H. Comparison of mobile-phase systems commonly applied in liquid chromatography-mass spectrometry of nucleic acids. Electrophoresis. 2014;35:1226–35.CrossRefPubMedGoogle Scholar
  29. 29.
    Basiri B, van Hattum H, van Dongen WD, Murph MM, Bartlett MG. The role of fluorinated alcohols as mobile phase modifiers for LC-MS analysis of oligonucleotides. J Am Soc Mass Spectrom. 2017;28:190–9.CrossRefPubMedGoogle Scholar
  30. 30.
    Nyakas A, Blum LC, Stucki SR, Reymond JL, Schurch S. OMA and OPA—software-supported mass spectra analysis of native and modified nucleic acids. J Am Soc Mass Spectrom. 2013;24:249–56.CrossRefPubMedGoogle Scholar
  31. 31.
    Murray KK, Boyd RK, Eberlin MN, Langley GJ, Li L, Naito Y. Definitions of terms relating to mass spectrometry (IUPAC recommendations 2013). Pure Appl Chem. 2013;85:1515–609.CrossRefGoogle Scholar
  32. 32.
    Greer S, Zamenhof S. Studies on depurination of DNA by heat. J Mol Biol. 1962;4:123–41.CrossRefPubMedGoogle Scholar
  33. 33.
    Crooke RM, Graham MJ, Martin MJ, Lemonidis KM, Wyrzykiewiecz T, Cummins LL. Metabolism of antisense oligonucleotides in rat liver homogenates. J Pharmacol Exp Ther. 2000;292:140–9.PubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • N. M. Elzahar
    • 1
    • 2
  • N. Magdy
    • 1
  • Amira M. El-Kosasy
    • 1
  • Michael G. Bartlett
    • 2
  1. 1.Pharmaceutical Analytical Chemistry Department, Faculty of PharmacyAin Shams UniversityCairoEgypt
  2. 2.Department of Pharmaceutical and Biomedical Sciences, College of PharmacyUniversity of GeorgiaAthensUSA

Personalised recommendations